Inquiry Basket
JUN68744 is a useful peptide linker for synthesis of PSMA-617 (vipivotide tetraxetan), which is a ligand used to make 177Lu-PSMA-617, a radioactive molecule to fight cancer. PSMA-617 originally was developed at the German Cancer Research Center and the Heidelberg University Hospital. ABX held the exclusive license to bring the treatment, which targets prostate-specific membrane antigen (PSMA), through early clinical development.
| Catalog Number | Size | Price | Quantity | ||
|---|---|---|---|---|---|
| BADC-00615 | 100 mg | $1999 | Inquiry |
JUN68744 is a novel small molecule that has gained attention in the field of drug development, particularly in oncology. It is known for its ability to inhibit specific signaling pathways that are critical for cancer cell proliferation and survival. JUN68744 has shown promise as a targeted therapeutic agent, designed to block the activity of certain kinases or proteins involved in tumor growth. By interfering with these pathways, JUN68744 can potentially reduce tumor growth and metastasis, making it an attractive candidate for the treatment of various cancers, including those that are resistant to conventional therapies.
One of the key applications of JUN68744 is in the treatment of solid tumors, including lung, breast, and colorectal cancers. The compound works by inhibiting specific molecular targets that drive the growth and survival of cancer cells. For example, JUN68744 may target kinases involved in the regulation of cell cycle progression, apoptosis, or angiogenesis, which are often dysregulated in cancer. By modulating these pathways, JUN68744 has the potential to slow down or halt tumor progression, offering a new option for patients with cancers that are difficult to treat with standard chemotherapy or targeted therapies.
In addition to its use in solid tumors, JUN68744 is being explored for its potential to overcome drug resistance in cancer treatments. Many cancers develop resistance to traditional therapies over time, making them harder to treat effectively. JUN68744 may help to reverse or bypass some of these resistance mechanisms by targeting alternative pathways that cancer cells rely on for survival. This application could significantly enhance the efficacy of existing treatments and offer hope to patients with drug-resistant cancers, where few other options are available.
JUN68744 is also being investigated in combination therapy strategies. Researchers are exploring how this compound can be used alongside other cancer treatments, such as immune checkpoint inhibitors or other targeted agents, to enhance therapeutic outcomes. By combining JUN68744 with immunotherapy, for instance, it may help to sensitize tumors to immune attack, improving the overall effectiveness of the treatment. This approach could open up new avenues for more personalized and synergistic treatment regimens, improving patient outcomes in various types of cancer.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
